A
B
C
D
5. DPY30 loss impairs tumor growth only in immune-competent mice
E
F
G
H
I
6. DPY30 knockout tumors display higher CD8+ T cell infiltration and respond better to anti-PD-1
Conclusions: our findings indicate that, in PDAC, DPY30 promotes genome stability, thus providing a rationale for targeting DPY30 or its effector proteins in combination with immune-checkpoint inhibitors. This study is supported by AIRC and the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 800924 and by the 2020 AACR- AstraZeneca START Grant, Grant Number 20-40-12-CITR
Made with FlippingBook flipbook maker